A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1

Thrombosis Research

Volumn 97, Issue 6, 2000, Pages 463-472

  Bendz, Bjørn ^a   Andersen, Trine O ^a   Sandset, Per Morten ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chromogenic substrate assay; Factor VII; Factor X; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; I 2882; N BENZOYLISOLEUCYL GAMMA GLUTAMYLGLYCYLARGININE 4 NITROANILIDE; S 2765; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITOR INTERACTION; ENZYME REGULATION; FIBRIN POLYMERIZATION; HUMAN; IMMUNOASSAY; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033998697     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00183-8     Document Type: Article

References (29)

1. Sandset P.M., Larsen M.L., Abildgaard U., Lindahl A.K., Odegaard O.R. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI). levels in the normal population and relation to cholesterol Blood Coag Fibrinol. 2:1991;425-433.
2. Rapaport S.I., Rao L.V. The tissue factor pathway. how it has become a "prima ballerina." Thromb Haemost. 74:1995;7-17.
3. Hjort P.F. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scand J Clin Lab Invest. 9(Suppl 27):1957;1-173.
4. Dahl P.E., Abildgaard U., Larsen M.L., Tjensvoll L. Inhibition of activated coagulation factor VII by normal human plasma. Thromb Haemost. 48:1982;253-256.
5. Broze G.J. Jr., Miletich J.P. Characterization of the inhibition of tissue factor in serum. Blood. 69:1987;150-155.
6. Rao L.V., Rapaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 69:1987;645-651.
7. Sanders N.L., Bajaj S.P., Zivelin A., Rapaport S.I. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood. 66:1985;204-212.
8. Wun T.C., Kretzmer K.K., Girard T.J., Miletich J.P., Broze G.J. Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 263:1988;6001-6004.
9. Girard T.J., Warren L.A., Novotny W.F., Likert K.M., Brown S.G., Miletich J.P., Broze G.J. Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 338:1989;518-520.
10. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb Haemost. 74:1995;90-93.
11. Hubbard A.R., Weller L.J., Gray E. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma. Blood Coag Fibrinol. 5:1994;819-823.
12. Novotny W.F., Brown S.G., Miletich J.P., Rader D.J., Broze G.J. Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood. 78:1991;387-393.
13. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50:1988;803-813.
14. Hansen J.B., Huseby K.R., Huseby N.E., Sandset P.M., Hanssen T.A., Nordøy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol. 15:1995;879-885.
15. Hansen J.B., Huseby N.E., Sandset P.M., Svensson B., Lyngmo V., Nordøy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb. 14:1994;223-229.
16. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 264:1989;18832-18837.
17. Novotny W.F., Girard T.J., Miletich J.P., Broze G.J. Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood. 72:1988;2020-2025.
18. Lindahl A.K., Jacobsen P.B., Sandset P.M., Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 2:1991;713-721.
19. Hansen N.B., Huseby K.R., Huseby J.E., Ezban M., Nordøy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res. 85:1997;413-425.
20. Sandset P.M., Bendz B. Tissue factor pathway inhibitor. clinical deficiency states Thromb Haemost. 78:1997;467-470.
21. Bognacki J., Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coag Fibrinol. 6(Suppl 1):1995;S65-S72.
22. Sandset P.M., Abildgaard U., Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res. 47:1987;389-400.
23. Jeske W., Hoppensteadt D., Fareed J., Bermes E. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations. Blood Coag Fibrinol. 6(Suppl 1):1995;S73-S80.
24. Hoogendoorn H., Cerskus A., Ofosu F., Blajchman M., Hirsh J. Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. Thromb Res. 20:1980;77-83.
25. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1:1986;307-310.
26. Warr T.A., Warn-Cramer B.J., Rao L.V., Rapaport S.I. Human plasma extrinsic pathway inhibitor activity. I. Standardization of assay and evaluation of physiologic variables Blood. 74:1989;201-206.
27. Sakkinen P.A., Cushman M., Psaty B.M., Kuller L.H., Bajaj S.P., Sabharwal A.K., Boineau R., Macy E., Tracy R.P. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost. 80:1998;134-139.
28. Hansen J.B., Sandset P.M., Huseby K.R., Huseby N.E., Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 76:1996;703-709.
29. Broze G.J. Jr., Lange G.W., Duffin K.L., MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coag Fibrinol. 5:1994;551-559.